Search

Pomalidomide prolongs survival in refractory myeloma patients

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Read more

EHA-SWG Scientific Meeting on New Molecular Insights and Innovative Management Approaches for Acute Lymphoblastic Leukemia

Dates: April 12-14, 2018
Location: Barcelona, Spain
Chair: N Gökbuget
Co-chairs: R Bassan, H Dombret, A Fielding, R Foà, D Hoelzer, JM Ribera

EHA and the EHA Scientific Working Group on Acute Lymphoblastic Leukemia are organizing their second EHA-SWG Scientific Meeting on Acute Lymphoblastic Leukemia.…

Read more

EHA-Balkan Hematology Day 2023

EHA is joining forces with the national societies from the Balkan countries and co-organizing with them the 4th edition of the EHA-Balkan Hematology Day.

Read more

EHA-Balkan Hematology Day 2021

EHA is joining forces with the national societies from the Balkan countries and co-organizing with them the 2nd edition of the EHA-Balkan Hematology Day.

Read more

EHA Endorsement of ESMO Clinical Practice Guidelines on Hodgkin Lymphoma

EHA and ESMO agreed to collaborate in the production of European Guidelines for different hematological malignancies. For the second workshop in the series participants joined us for the EHA Endorsement of ESMO Clinical Practice Guidelines on Hodgkin Lymphoma.

Read more